| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Retinopathy | 74 | 2024 | 178 | 23.360 |
Why?
|
| Macular Edema | 53 | 2024 | 99 | 16.060 |
Why?
|
| Angiogenesis Inhibitors | 93 | 2024 | 1248 | 13.080 |
Why?
|
| Ranibizumab | 57 | 2023 | 74 | 10.980 |
Why?
|
| Visual Acuity | 87 | 2023 | 873 | 10.490 |
Why?
|
| Wet Macular Degeneration | 31 | 2023 | 35 | 10.120 |
Why?
|
| Macular Degeneration | 26 | 2023 | 114 | 9.380 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 47 | 2024 | 355 | 8.800 |
Why?
|
| Intravitreal Injections | 89 | 2023 | 141 | 8.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 78 | 2023 | 1533 | 7.060 |
Why?
|
| Recombinant Fusion Proteins | 47 | 2024 | 1555 | 7.010 |
Why?
|
| Tomography, Optical Coherence | 68 | 2023 | 501 | 6.350 |
Why?
|
| Fluorescein Angiography | 54 | 2023 | 139 | 6.140 |
Why?
|
| Geographic Atrophy | 11 | 2023 | 15 | 5.440 |
Why?
|
| Retinal Detachment | 15 | 2023 | 88 | 5.030 |
Why?
|
| Diabetes Mellitus | 19 | 2024 | 1054 | 4.960 |
Why?
|
| Retinal Vein Occlusion | 17 | 2022 | 29 | 4.820 |
Why?
|
| Choroidal Neovascularization | 12 | 2023 | 29 | 4.710 |
Why?
|
| Retinal Diseases | 14 | 2022 | 179 | 4.580 |
Why?
|
| Macula Lutea | 16 | 2022 | 47 | 4.430 |
Why?
|
| Vitrectomy | 23 | 2024 | 100 | 4.380 |
Why?
|
| Laser Coagulation | 17 | 2023 | 136 | 3.950 |
Why?
|
| Retinal Vessels | 23 | 2023 | 85 | 3.870 |
Why?
|
| Retinal Perforations | 8 | 2023 | 31 | 2.810 |
Why?
|
| Retina | 22 | 2023 | 532 | 2.760 |
Why?
|
| Antibodies, Monoclonal, Humanized | 20 | 2023 | 3251 | 2.690 |
Why?
|
| Bevacizumab | 19 | 2023 | 938 | 2.460 |
Why?
|
| Scleral Buckling | 9 | 2022 | 12 | 2.350 |
Why?
|
| Endophthalmitis | 7 | 2016 | 84 | 2.190 |
Why?
|
| Glucocorticoids | 8 | 2020 | 629 | 1.860 |
Why?
|
| Photography | 6 | 2022 | 139 | 1.740 |
Why?
|
| Ischemia | 10 | 2021 | 391 | 1.650 |
Why?
|
| Peptides, Cyclic | 2 | 2023 | 139 | 1.610 |
Why?
|
| Humans | 202 | 2024 | 261506 | 1.440 |
Why?
|
| Prospective Studies | 46 | 2023 | 12873 | 1.320 |
Why?
|
| Fovea Centralis | 4 | 2020 | 23 | 1.280 |
Why?
|
| Retinal Vasculitis | 4 | 2023 | 10 | 1.250 |
Why?
|
| Eye Infections, Bacterial | 3 | 2016 | 96 | 1.250 |
Why?
|
| Choroid | 5 | 2021 | 35 | 1.230 |
Why?
|
| Complement C3 | 3 | 2021 | 78 | 1.140 |
Why?
|
| Endothelial Growth Factors | 10 | 2023 | 197 | 1.130 |
Why?
|
| Middle Aged | 82 | 2024 | 86204 | 1.070 |
Why?
|
| Male | 99 | 2024 | 123000 | 1.050 |
Why?
|
| Aged | 72 | 2024 | 70117 | 1.020 |
Why?
|
| Epiretinal Membrane | 3 | 2023 | 13 | 1.000 |
Why?
|
| Female | 101 | 2024 | 141928 | 0.990 |
Why?
|
| Triamcinolone Acetonide | 3 | 2020 | 38 | 0.990 |
Why?
|
| Retinal Pigment Epithelium | 4 | 2021 | 37 | 0.990 |
Why?
|
| Fluocinolone Acetonide | 4 | 2020 | 4 | 0.980 |
Why?
|
| Complement Inactivating Agents | 2 | 2021 | 16 | 0.970 |
Why?
|
| Fundus Oculi | 14 | 2023 | 74 | 0.960 |
Why?
|
| Treatment Outcome | 46 | 2024 | 32848 | 0.940 |
Why?
|
| Subretinal Fluid | 6 | 2022 | 10 | 0.920 |
Why?
|
| Retinal Vein | 3 | 2022 | 11 | 0.910 |
Why?
|
| Cataract | 3 | 2022 | 218 | 0.890 |
Why?
|
| Cysts | 2 | 2024 | 197 | 0.880 |
Why?
|
| Follow-Up Studies | 28 | 2022 | 14889 | 0.870 |
Why?
|
| Eye Infections, Fungal | 4 | 2014 | 71 | 0.850 |
Why?
|
| Retinal Telangiectasis | 2 | 2023 | 3 | 0.830 |
Why?
|
| Benchmarking | 1 | 2023 | 273 | 0.800 |
Why?
|
| Ophthalmoscopy | 3 | 2019 | 35 | 0.780 |
Why?
|
| Ophthalmic Solutions | 2 | 2011 | 101 | 0.780 |
Why?
|
| Retrospective Studies | 44 | 2023 | 37905 | 0.780 |
Why?
|
| Aged, 80 and over | 34 | 2023 | 29902 | 0.760 |
Why?
|
| Edema | 2 | 2022 | 267 | 0.760 |
Why?
|
| No-Show Patients | 1 | 2020 | 4 | 0.750 |
Why?
|
| Vitreoretinal Surgery | 2 | 2021 | 7 | 0.740 |
Why?
|
| Vision Disorders | 4 | 2023 | 245 | 0.740 |
Why?
|
| Cataract Extraction | 3 | 2017 | 184 | 0.740 |
Why?
|
| Lost to Follow-Up | 1 | 2020 | 34 | 0.730 |
Why?
|
| Retinal Hemorrhage | 2 | 2017 | 26 | 0.730 |
Why?
|
| Sensory Thresholds | 1 | 2019 | 68 | 0.700 |
Why?
|
| Vitreous Body | 4 | 2023 | 123 | 0.690 |
Why?
|
| Patient Dropouts | 1 | 2019 | 88 | 0.680 |
Why?
|
| Choroid Diseases | 1 | 2019 | 26 | 0.670 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2019 | 461 | 0.660 |
Why?
|
| Eye Diseases | 2 | 2011 | 132 | 0.650 |
Why?
|
| Ophthalmology | 4 | 2023 | 198 | 0.640 |
Why?
|
| Antibodies, Bispecific | 1 | 2022 | 246 | 0.640 |
Why?
|
| Microaneurysm | 3 | 2023 | 3 | 0.640 |
Why?
|
| Monitoring, Physiologic | 1 | 2020 | 502 | 0.590 |
Why?
|
| Adult | 43 | 2024 | 77950 | 0.590 |
Why?
|
| Clinical Trials as Topic | 5 | 2023 | 3719 | 0.590 |
Why?
|
| Double-Blind Method | 11 | 2023 | 2588 | 0.580 |
Why?
|
| Lasers | 2 | 2017 | 198 | 0.570 |
Why?
|
| Lasers, Solid-State | 1 | 2016 | 16 | 0.550 |
Why?
|
| Postoperative Complications | 4 | 2017 | 5542 | 0.550 |
Why?
|
| Retinitis | 1 | 2016 | 19 | 0.550 |
Why?
|
| Meningoencephalitis | 1 | 2016 | 24 | 0.540 |
Why?
|
| Drug Delivery Systems | 2 | 2022 | 669 | 0.530 |
Why?
|
| Patient Compliance | 1 | 2019 | 667 | 0.520 |
Why?
|
| Vancomycin | 1 | 2017 | 273 | 0.510 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 181 | 0.500 |
Why?
|
| Povidone-Iodine | 2 | 2011 | 21 | 0.490 |
Why?
|
| Anti-Bacterial Agents | 5 | 2019 | 2992 | 0.490 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2018 | 273 | 0.480 |
Why?
|
| Basement Membrane | 4 | 2023 | 138 | 0.480 |
Why?
|
| West Nile Fever | 1 | 2016 | 151 | 0.470 |
Why?
|
| Vitreous Detachment | 2 | 2023 | 12 | 0.460 |
Why?
|
| Clinical Protocols | 5 | 2022 | 467 | 0.450 |
Why?
|
| Disease Progression | 11 | 2022 | 6682 | 0.450 |
Why?
|
| Fungi | 3 | 2014 | 145 | 0.430 |
Why?
|
| Vitreoretinopathy, Proliferative | 2 | 2022 | 5 | 0.430 |
Why?
|
| Neovascularization, Pathologic | 3 | 2018 | 1547 | 0.420 |
Why?
|
| Choroid Neoplasms | 2 | 2013 | 41 | 0.420 |
Why?
|
| Cryosurgery | 1 | 2013 | 167 | 0.420 |
Why?
|
| Antisepsis | 1 | 2011 | 12 | 0.410 |
Why?
|
| Drug Administration Schedule | 6 | 2022 | 3472 | 0.410 |
Why?
|
| Ciliary Body | 1 | 2011 | 35 | 0.400 |
Why?
|
| Retinal Neovascularization | 3 | 2020 | 20 | 0.400 |
Why?
|
| Eye | 2 | 2024 | 301 | 0.390 |
Why?
|
| Bacteria | 2 | 2016 | 611 | 0.390 |
Why?
|
| Atrophy | 5 | 2023 | 261 | 0.380 |
Why?
|
| Retinal Degeneration | 2 | 2023 | 85 | 0.380 |
Why?
|
| Angiopoietin-2 | 2 | 2022 | 38 | 0.380 |
Why?
|
| Time Factors | 9 | 2021 | 12926 | 0.380 |
Why?
|
| Cephalosporins | 1 | 2011 | 148 | 0.360 |
Why?
|
| Hospitals, University | 1 | 2010 | 209 | 0.360 |
Why?
|
| Surgical Wound Infection | 2 | 2017 | 450 | 0.360 |
Why?
|
| Regional Blood Flow | 3 | 2019 | 276 | 0.350 |
Why?
|
| Drug Hypersensitivity | 1 | 2011 | 128 | 0.350 |
Why?
|
| Retreatment | 4 | 2018 | 452 | 0.350 |
Why?
|
| Uveal Neoplasms | 1 | 2011 | 176 | 0.340 |
Why?
|
| Mycoses | 2 | 2014 | 386 | 0.340 |
Why?
|
| Aging | 1 | 2018 | 1582 | 0.340 |
Why?
|
| Oculomotor Nerve | 1 | 2008 | 6 | 0.340 |
Why?
|
| Precision Medicine | 2 | 2018 | 1154 | 0.330 |
Why?
|
| Cryptococcosis | 1 | 2009 | 63 | 0.330 |
Why?
|
| Regression Analysis | 3 | 2022 | 1546 | 0.330 |
Why?
|
| Blindness | 2 | 2021 | 77 | 0.330 |
Why?
|
| Pharmaceutical Preparations | 3 | 2023 | 152 | 0.330 |
Why?
|
| Oculomotor Nerve Diseases | 1 | 2008 | 27 | 0.320 |
Why?
|
| Capillary Permeability | 2 | 2020 | 114 | 0.320 |
Why?
|
| Eye Injuries, Penetrating | 1 | 2008 | 23 | 0.320 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2008 | 49 | 0.320 |
Why?
|
| Monitoring, Intraoperative | 1 | 2010 | 264 | 0.320 |
Why?
|
| Exudates and Transudates | 2 | 2021 | 52 | 0.320 |
Why?
|
| Corneal Ulcer | 1 | 2008 | 49 | 0.310 |
Why?
|
| Biomarkers | 7 | 2023 | 5047 | 0.310 |
Why?
|
| Rhabdoid Tumor | 1 | 2008 | 110 | 0.310 |
Why?
|
| Single-Blind Method | 2 | 2021 | 409 | 0.290 |
Why?
|
| Teratoma | 1 | 2008 | 236 | 0.280 |
Why?
|
| Cross Infection | 1 | 2010 | 544 | 0.270 |
Why?
|
| Network Meta-Analysis | 2 | 2022 | 31 | 0.260 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2022 | 2594 | 0.260 |
Why?
|
| Quality of Life | 4 | 2023 | 4532 | 0.260 |
Why?
|
| Algorithms | 5 | 2023 | 3890 | 0.260 |
Why?
|
| Keratomileusis, Laser In Situ | 1 | 2006 | 129 | 0.250 |
Why?
|
| Aqueous Humor | 2 | 2022 | 29 | 0.250 |
Why?
|
| Angiopoietins | 2 | 2021 | 35 | 0.240 |
Why?
|
| Myopia | 1 | 2006 | 194 | 0.240 |
Why?
|
| Entropy | 1 | 2023 | 37 | 0.240 |
Why?
|
| Photochemotherapy | 2 | 2022 | 96 | 0.230 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2023 | 15 | 0.230 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 4320 | 0.230 |
Why?
|
| Antibodies, Monoclonal | 2 | 2019 | 4367 | 0.220 |
Why?
|
| Delphi Technique | 1 | 2023 | 210 | 0.220 |
Why?
|
| Traction | 1 | 2022 | 13 | 0.220 |
Why?
|
| Risk Factors | 8 | 2023 | 17523 | 0.210 |
Why?
|
| Central Serous Chorioretinopathy | 1 | 2022 | 7 | 0.210 |
Why?
|
| Porphyrins | 1 | 2022 | 37 | 0.210 |
Why?
|
| Prone Position | 1 | 2022 | 56 | 0.210 |
Why?
|
| Cross-Sectional Studies | 6 | 2021 | 4314 | 0.210 |
Why?
|
| Uveitis | 1 | 2022 | 33 | 0.210 |
Why?
|
| Drug Resistance | 2 | 2013 | 587 | 0.200 |
Why?
|
| Blood-Retinal Barrier | 2 | 2020 | 6 | 0.200 |
Why?
|
| Drug Implants | 2 | 2020 | 46 | 0.200 |
Why?
|
| Cornea | 1 | 2006 | 638 | 0.200 |
Why?
|
| Intraocular Pressure | 1 | 2021 | 146 | 0.190 |
Why?
|
| Computer Systems | 1 | 2021 | 106 | 0.190 |
Why?
|
| Biomedical Research | 2 | 2019 | 806 | 0.190 |
Why?
|
| Videoconferencing | 1 | 2020 | 56 | 0.180 |
Why?
|
| Postoperative Period | 2 | 2020 | 665 | 0.180 |
Why?
|
| Confidence Intervals | 1 | 2021 | 756 | 0.180 |
Why?
|
| Equipment Design | 2 | 2020 | 1204 | 0.180 |
Why?
|
| Eye Neoplasms | 2 | 2013 | 247 | 0.180 |
Why?
|
| Registries | 3 | 2023 | 2170 | 0.180 |
Why?
|
| Fractals | 1 | 2019 | 11 | 0.180 |
Why?
|
| Injections, Intraocular | 1 | 2019 | 8 | 0.170 |
Why?
|
| Consensus | 1 | 2023 | 978 | 0.170 |
Why?
|
| Combined Modality Therapy | 7 | 2020 | 8865 | 0.170 |
Why?
|
| Income | 1 | 2020 | 222 | 0.170 |
Why?
|
| Ophthalmologists | 1 | 2019 | 14 | 0.170 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2019 | 153 | 0.170 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2020 | 255 | 0.160 |
Why?
|
| Congresses as Topic | 1 | 2020 | 298 | 0.160 |
Why?
|
| Microcirculation | 1 | 2019 | 200 | 0.160 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 208 | 0.160 |
Why?
|
| Visual Prosthesis | 1 | 2017 | 1 | 0.160 |
Why?
|
| Early Diagnosis | 1 | 2019 | 298 | 0.160 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2019 | 104 | 0.160 |
Why?
|
| Vision, Low | 1 | 2017 | 18 | 0.160 |
Why?
|
| Biological Products | 1 | 2021 | 274 | 0.160 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 4744 | 0.160 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 225 | 0.150 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 1945 | 0.150 |
Why?
|
| Insurance Coverage | 1 | 2020 | 256 | 0.150 |
Why?
|
| Cytokines | 3 | 2022 | 2809 | 0.150 |
Why?
|
| Adolescent | 5 | 2024 | 31252 | 0.150 |
Why?
|
| Retinitis Pigmentosa | 1 | 2017 | 79 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 945 | 0.150 |
Why?
|
| Drug and Narcotic Control | 1 | 2016 | 31 | 0.140 |
Why?
|
| Legislation, Drug | 1 | 2016 | 17 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2020 | 4938 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 799 | 0.140 |
Why?
|
| Beryllium | 1 | 2016 | 3 | 0.140 |
Why?
|
| Young Adult | 6 | 2021 | 21445 | 0.140 |
Why?
|
| Oxygen | 3 | 2018 | 754 | 0.140 |
Why?
|
| United States | 7 | 2023 | 15433 | 0.140 |
Why?
|
| Administration, Topical | 1 | 2016 | 257 | 0.140 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2015 | 33 | 0.130 |
Why?
|
| Therapeutic Equivalency | 1 | 2015 | 49 | 0.130 |
Why?
|
| Prosthesis Implantation | 1 | 2017 | 263 | 0.130 |
Why?
|
| Antifungal Agents | 3 | 2014 | 834 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.130 |
Why?
|
| Melanoma | 2 | 2013 | 5317 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 573 | 0.130 |
Why?
|
| Recurrence | 2 | 2019 | 4758 | 0.120 |
Why?
|
| Fluconazole | 2 | 2014 | 103 | 0.110 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 2315 | 0.110 |
Why?
|
| Surgical Flaps | 1 | 2020 | 927 | 0.110 |
Why?
|
| History, 18th Century | 1 | 2013 | 89 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2018 | 492 | 0.110 |
Why?
|
| Amphotericin B | 2 | 2014 | 289 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.110 |
Why?
|
| Neoplasm Proteins | 5 | 2004 | 3230 | 0.110 |
Why?
|
| Cohort Studies | 5 | 2022 | 9244 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.110 |
Why?
|
| Observational Studies as Topic | 2 | 2023 | 140 | 0.100 |
Why?
|
| Telemedicine | 1 | 2018 | 471 | 0.100 |
Why?
|
| Electronic Health Records | 1 | 2020 | 929 | 0.100 |
Why?
|
| Anterior Chamber | 1 | 2012 | 51 | 0.100 |
Why?
|
| Blood Glucose | 1 | 2016 | 1244 | 0.100 |
Why?
|
| Chlorhexidine | 1 | 2011 | 88 | 0.100 |
Why?
|
| Liver Function Tests | 1 | 2011 | 173 | 0.100 |
Why?
|
| Retinopathy of Prematurity | 1 | 2011 | 88 | 0.100 |
Why?
|
| Ultrasonography | 2 | 2009 | 1863 | 0.100 |
Why?
|
| Refraction, Ocular | 1 | 2013 | 289 | 0.100 |
Why?
|
| Florida | 1 | 2010 | 113 | 0.090 |
Why?
|
| Penicillins | 1 | 2011 | 143 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 1303 | 0.090 |
Why?
|
| Drug Costs | 1 | 2011 | 144 | 0.090 |
Why?
|
| Cell Hypoxia | 4 | 2004 | 328 | 0.090 |
Why?
|
| Flucytosine | 1 | 2009 | 30 | 0.090 |
Why?
|
| Cryptococcus neoformans | 1 | 2009 | 27 | 0.090 |
Why?
|
| Glucose | 1 | 2015 | 1248 | 0.080 |
Why?
|
| Carbonic Anhydrases | 3 | 2003 | 44 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 2403 | 0.080 |
Why?
|
| Subarachnoid Space | 1 | 2008 | 36 | 0.080 |
Why?
|
| Laser Therapy | 1 | 2013 | 411 | 0.080 |
Why?
|
| Mesencephalon | 1 | 2008 | 58 | 0.080 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2008 | 31 | 0.080 |
Why?
|
| Keratoplasty, Penetrating | 1 | 2008 | 48 | 0.080 |
Why?
|
| Eye Enucleation | 1 | 2008 | 91 | 0.080 |
Why?
|
| Age Factors | 1 | 2018 | 5377 | 0.080 |
Why?
|
| Acute Disease | 2 | 2010 | 2422 | 0.080 |
Why?
|
| Intraoperative Complications | 1 | 2010 | 301 | 0.080 |
Why?
|
| Decision Making | 1 | 2015 | 1287 | 0.080 |
Why?
|
| Antigens, Neoplasm | 3 | 2003 | 1506 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2021 | 447 | 0.080 |
Why?
|
| Body Weights and Measures | 1 | 2006 | 52 | 0.070 |
Why?
|
| Hydrocephalus | 1 | 2008 | 217 | 0.070 |
Why?
|
| Capillaries | 2 | 2017 | 99 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2008 | 829 | 0.070 |
Why?
|
| Transcription Factors | 4 | 2004 | 5270 | 0.070 |
Why?
|
| Incidence | 1 | 2016 | 5673 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2008 | 1391 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2011 | 1529 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2012 | 5319 | 0.060 |
Why?
|
| Search Engine | 1 | 2023 | 21 | 0.060 |
Why?
|
| Vitreous Hemorrhage | 1 | 2023 | 11 | 0.060 |
Why?
|
| Nuclear Proteins | 3 | 2004 | 3343 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2021 | 11965 | 0.060 |
Why?
|
| Neurosurgical Procedures | 1 | 2008 | 609 | 0.060 |
Why?
|
| Equivalence Trials as Topic | 1 | 2023 | 23 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2023 | 30 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 1162 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2023 | 212 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2020 | 2803 | 0.050 |
Why?
|
| Biomarkers, Tumor | 4 | 2008 | 10331 | 0.050 |
Why?
|
| Nephrons | 1 | 2002 | 48 | 0.050 |
Why?
|
| Pandemics | 2 | 2023 | 1559 | 0.050 |
Why?
|
| Neurofibromin 2 | 1 | 2022 | 39 | 0.050 |
Why?
|
| Syringes | 1 | 2022 | 42 | 0.050 |
Why?
|
| Indocyanine Green | 2 | 2015 | 117 | 0.050 |
Why?
|
| Pentosan Sulfuric Polyester | 1 | 2021 | 1 | 0.050 |
Why?
|
| Photosensitizing Agents | 1 | 2022 | 71 | 0.050 |
Why?
|
| DNA-Binding Proteins | 3 | 2004 | 4821 | 0.050 |
Why?
|
| Cell Adhesion Molecule-1 | 1 | 2021 | 3 | 0.050 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2021 | 17 | 0.050 |
Why?
|
| Canada | 1 | 2022 | 429 | 0.050 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2002 | 115 | 0.050 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2002 | 178 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2021 | 66 | 0.050 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2021 | 157 | 0.050 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2021 | 136 | 0.050 |
Why?
|
| Inflammation | 2 | 2022 | 2522 | 0.050 |
Why?
|
| Slit Lamp Microscopy | 1 | 2020 | 6 | 0.050 |
Why?
|
| Iatrogenic Disease | 1 | 2021 | 183 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 3981 | 0.050 |
Why?
|
| Organ Size | 1 | 2022 | 690 | 0.050 |
Why?
|
| Observation | 1 | 2020 | 48 | 0.050 |
Why?
|
| Half-Life | 1 | 2020 | 259 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 543 | 0.050 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2019 | 99 | 0.040 |
Why?
|
| Lung Neoplasms | 3 | 2012 | 11538 | 0.040 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2002 | 445 | 0.040 |
Why?
|
| Hypoxia-Inducible Factor 1 | 3 | 2004 | 55 | 0.040 |
Why?
|
| Carbonic Anhydrase IX | 3 | 2003 | 36 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 1064 | 0.040 |
Why?
|
| Medicare | 1 | 2023 | 860 | 0.040 |
Why?
|
| Specialization | 1 | 2019 | 130 | 0.040 |
Why?
|
| Anesthetics, Local | 1 | 2019 | 163 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 4971 | 0.040 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2002 | 674 | 0.040 |
Why?
|
| Electroretinography | 1 | 2017 | 116 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2003 | 1143 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 430 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2018 | 90 | 0.040 |
Why?
|
| Necrosis | 3 | 2004 | 580 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 6009 | 0.040 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2004 | 376 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2021 | 712 | 0.040 |
Why?
|
| European Union | 1 | 2016 | 18 | 0.040 |
Why?
|
| Infant | 2 | 2011 | 13310 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2021 | 1038 | 0.040 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2020 | 592 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2004 | 1664 | 0.040 |
Why?
|
| Emergency Medical Services | 1 | 2021 | 429 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2021 | 787 | 0.030 |
Why?
|
| Research Design | 1 | 2023 | 1544 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2015 | 87 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2017 | 749 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 1489 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 860 | 0.030 |
Why?
|
| Internet | 1 | 2019 | 706 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2011 | 4557 | 0.030 |
Why?
|
| Voriconazole | 1 | 2014 | 108 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2018 | 550 | 0.030 |
Why?
|
| COS Cells | 2 | 2004 | 377 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2002 | 2045 | 0.030 |
Why?
|
| Visual Fields | 1 | 2014 | 142 | 0.030 |
Why?
|
| Light Coagulation | 1 | 2013 | 18 | 0.030 |
Why?
|
| Protein Binding | 1 | 2020 | 3438 | 0.030 |
Why?
|
| Phenotype | 2 | 2021 | 6295 | 0.030 |
Why?
|
| Child | 2 | 2011 | 29154 | 0.030 |
Why?
|
| Observer Variation | 1 | 2014 | 671 | 0.030 |
Why?
|
| Nevus | 1 | 2013 | 107 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 7702 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 3441 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2022 | 16273 | 0.030 |
Why?
|
| Hemangioma | 1 | 2013 | 154 | 0.030 |
Why?
|
| Retinal Neoplasms | 1 | 2013 | 144 | 0.020 |
Why?
|
| Retinoblastoma | 1 | 2013 | 200 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2014 | 994 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 598 | 0.020 |
Why?
|
| In Situ Hybridization | 2 | 2004 | 1037 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2019 | 830 | 0.020 |
Why?
|
| RNA, Neoplasm | 2 | 2004 | 771 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2008 | 10035 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 2 | 2002 | 1165 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2014 | 785 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2002 | 2326 | 0.020 |
Why?
|
| Prognosis | 3 | 2021 | 21713 | 0.020 |
Why?
|
| Mass Screening | 1 | 2018 | 1509 | 0.020 |
Why?
|
| Fluorescence | 1 | 2009 | 195 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2009 | 234 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 3260 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2002 | 3022 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 1362 | 0.020 |
Why?
|
| Hyperthermia, Induced | 1 | 2013 | 510 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 551 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2002 | 8873 | 0.020 |
Why?
|
| Syndrome | 1 | 2009 | 1351 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 15862 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 2013 | 1411 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2003 | 5395 | 0.020 |
Why?
|
| Mixed Function Oxygenases | 1 | 2004 | 64 | 0.020 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2004 | 46 | 0.020 |
Why?
|
| Immune Sera | 1 | 2004 | 146 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2004 | 52 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2004 | 6150 | 0.020 |
Why?
|
| Immediate-Early Proteins | 1 | 2004 | 107 | 0.010 |
Why?
|
| Doxycycline | 1 | 2004 | 178 | 0.010 |
Why?
|
| Survival | 1 | 2003 | 177 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2004 | 875 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2004 | 886 | 0.010 |
Why?
|
| RNA Probes | 1 | 2002 | 44 | 0.010 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2002 | 61 | 0.010 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2002 | 48 | 0.010 |
Why?
|
| Plasmids | 1 | 2004 | 837 | 0.010 |
Why?
|
| Breast Neoplasms | 2 | 2004 | 15694 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2002 | 448 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 769 | 0.010 |
Why?
|
| Hypoxia | 1 | 2004 | 443 | 0.010 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2002 | 171 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2003 | 614 | 0.010 |
Why?
|
| DNA Primers | 1 | 2002 | 1399 | 0.010 |
Why?
|
| RNA Interference | 1 | 2004 | 1408 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2004 | 2314 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2003 | 622 | 0.010 |
Why?
|
| RNA | 1 | 2004 | 1013 | 0.010 |
Why?
|
| Transfection | 1 | 2004 | 2944 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 2074 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 891 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2011 | 8223 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2002 | 874 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2004 | 2216 | 0.010 |
Why?
|
| Neoplasms | 1 | 2004 | 15193 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2004 | 2450 | 0.010 |
Why?
|
| Nephrectomy | 1 | 2002 | 779 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2002 | 1385 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 3536 | 0.010 |
Why?
|
| Cell Line | 1 | 2004 | 5114 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2002 | 2508 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 3639 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 3154 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2002 | 1439 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2003 | 4298 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2002 | 2022 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 4053 | 0.010 |
Why?
|
| Lung | 1 | 2003 | 3151 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 7548 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2003 | 9180 | 0.010 |
Why?
|
| Animals | 2 | 2004 | 59536 | 0.010 |
Why?
|
| Apoptosis | 1 | 2002 | 7591 | 0.000 |
Why?
|
| Mice | 1 | 2004 | 34495 | 0.000 |
Why?
|